Company news
Instil Bio, Inc. news in 2025
Instil Bio, Inc.'s news releases, calls and decks from 2025, newest first.
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
September 10, 2025
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed, Refractory Solid Tumors
July 3, 2025
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 2, 2025
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
June 11, 2025
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
June 2, 2025
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
May 30, 2025
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
May 23, 2025
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
May 22, 2025
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 4, 2025
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
January 13, 2025
Decks in 2025
- Investor Presentation (May 2025)
Investor deck · 18 slides · May 22, 2025
- Corporate Update (March 2025)
Corporate update · 9 slides · Mar 4, 2025